HK1247217A1 - 結合血管生成素2的抗體與結合編程性死亡配體1的抗體的組合療法 - Google Patents

結合血管生成素2的抗體與結合編程性死亡配體1的抗體的組合療法

Info

Publication number
HK1247217A1
HK1247217A1 HK18106727.7A HK18106727A HK1247217A1 HK 1247217 A1 HK1247217 A1 HK 1247217A1 HK 18106727 A HK18106727 A HK 18106727A HK 1247217 A1 HK1247217 A1 HK 1247217A1
Authority
HK
Hong Kong
Prior art keywords
antibody binding
angiopoietin
combination therapy
programmed death
death ligand
Prior art date
Application number
HK18106727.7A
Other languages
English (en)
Inventor
Frank Herting
Hans-Joachim Mueller
Original Assignee
豪夫邁•羅氏有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 豪夫邁•羅氏有限公司 filed Critical 豪夫邁•羅氏有限公司
Publication of HK1247217A1 publication Critical patent/HK1247217A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK18106727.7A 2015-04-23 2018-05-24 結合血管生成素2的抗體與結合編程性死亡配體1的抗體的組合療法 HK1247217A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15164803 2015-04-23
PCT/EP2016/058870 WO2016170040A1 (en) 2015-04-23 2016-04-21 Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1

Publications (1)

Publication Number Publication Date
HK1247217A1 true HK1247217A1 (zh) 2018-09-21

Family

ID=52997970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106727.7A HK1247217A1 (zh) 2015-04-23 2018-05-24 結合血管生成素2的抗體與結合編程性死亡配體1的抗體的組合療法

Country Status (7)

Country Link
US (1) US20180155431A1 (zh)
EP (1) EP3286217A1 (zh)
JP (1) JP2018515450A (zh)
CN (1) CN107406502A (zh)
AR (1) AR104361A1 (zh)
HK (1) HK1247217A1 (zh)
WO (1) WO2016170040A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding antibodies against PDL1 and methods for their preparation
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
US10596257B2 (en) 2016-01-08 2020-03-24 Hoffmann-La Roche Inc. Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
US11198726B2 (en) 2017-06-02 2021-12-14 Boerhinger Ingelheim International Gmbh Anti-cancer combination therapy
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4209510T (lt) * 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP2855528B1 (en) * 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists

Also Published As

Publication number Publication date
WO2016170040A1 (en) 2016-10-27
EP3286217A1 (en) 2018-02-28
CN107406502A (zh) 2017-11-28
JP2018515450A (ja) 2018-06-14
US20180155431A1 (en) 2018-06-07
AR104361A1 (es) 2017-07-12

Similar Documents

Publication Publication Date Title
HK1247217A1 (zh) 結合血管生成素2的抗體與結合編程性死亡配體1的抗體的組合療法
IL290488A (en) Therapeutic antibodies and their uses
IL272572B (en) Antibody preparations to treat cancer
IL261395A (en) Combined treatment with antibodies against cd73
HK1255107A1 (zh) 靶向分子的抗原結合構建體
ZA201905341B (en) Antibodies specifically binding to human il-1r7
EP3206491A4 (en) Use of methylnaltrexone to attenuate tumor progression
IL251676A0 (en) Antibodies that bind to ccr6 and their uses
HK1259445A1 (zh) 治療癌症的組合
GB201601663D0 (en) Direct incorporation of iron complexes into sapo-34 (CHA) type materials
PT3194976T (pt) Métodos para selecionar agentes que estabilizam complexos proteicos
SG11201704500VA (en) Antibody binding to neuropilin 1 and use thereof
ZA201802831B (en) Composition for the treatment of igf-1r expressing cancer
IL266540A (en) Intestinal expression of programmed death ligand 1
ZA201901862B (en) Modified factor h binding protein
PL3362480T3 (pl) Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie
GB201613172D0 (en) Combustion therapy
GB201404855D0 (en) Therapy moisturising candle
GB201410990D0 (en) General cure to diseases